Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 20
HOS-086303 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism,
Pravastatin, Rosuvastatin, Simvastatin such as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent
or as a pharmacokinetic enhancer. Since increased concentrations of lovastatin and
simvastatin may predispose patients to myopathies, including rhabdomyolysis, the
combination of these medicinal products with ritonavir is contraindicated (see
section 4.3). Atorvastatin is less dependent on CYP3A for metabolism. While
rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin
exposure has been reported with ritonavir co-administration. The mechanism of this
interaction is not clear, but may be the result of transporter inhibition. When used
with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the
lowest possible doses of atorvastatin or rosuvastatin should be administered. The
metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and
interactions are not expected with ritonavir. If treatment with an HMG-CoA
reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9aca472a9605d2ce92f2e3c73c3d58774cec61e0cad5a2ae7e9aa807365f0d07 · Zeichen 43147–44996 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086472 · Präparat HOS-083284
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such
Pravstatin, Rosuvastatin, Simvastatin as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as
a pharmacokinetic enhancer. Since increased concentrations of lovastatin and simvastatin
may predispose patients to myopathies, including rhabdomyolysis, the combination of
these medicinal products with ritonavir is contraindicated (see section 4.3). Atorvastatin
is less dependent on CYP3A for metabolism. While rosuvastatin elimination is not
dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with
ritonavir co-administration. The mechanism of this interaction is not clear, but may be
the result of transporter inhibition. When used with ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or
rosuvastatin should be administered. The metabolism of pravastatin and fluvastatin is not
dependent on CYP3A, and interactions are not expected with ritonavir. If treatment with
an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage aecf6db95f104726bea3f53130826841fcecb464a1fff5ff24afdad33e090079 · Zeichen 44359–46167 im Abschnitt
Wechselwirkungen · Xenical
Xenical 120 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-087481 · Präparat HOS-083511
Lack of interactions
No interactions with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan,
phenytoin, phentermine, pravastatin, nifedipine Gastrointestinal Therapeutic System (GITS),
nifedipine slow release, sibutramine or alcohol have been observed. The absence of these interactions
has been demonstrated in specific drug-drug-interaction studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) losartan (HOS-087482) amitriptyline (HOS-085911) atorvastatin (HOS-086304) digoxin (HOS-086172) phentermine (HOS-087483) sibutramine (HOS-087484) fluoxetine (HOS-085946) phenytoin (HOS-084531) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-10T13:00:00Z · SHA-256 632b9f6a72b3014c31eea28c23202ae6368254ac0e6429088389d3ea57a05739 · Passage 238caf08ee6a247653110f4663196875c65d11dc61039cdb333f880c45aa71f3 · Zeichen 2976–3358 im Abschnitt
Wechselwirkungen · Arava
Arava 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-089672 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5491–6465 im Abschnitt
Wechselwirkungen · Arava
Arava 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-089736 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5493–6467 im Abschnitt
Wechselwirkungen · Arava
Arava 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-089796 · Präparat HOS-083907
Effect on BCRP (Breast Cancer Resistance Protein) and /or organic anion transporting polypeptide
B1 and B3 (OATP1B1/B3) substrates
There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively),
following repeated doses of A771726. However, there was no apparent impact of this increase in
plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of
rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., methotrexate,
topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family especially HMG-CoA
reductase inhibitors (e.g., simvastatin, atorvastatin, pravastatin, methotrexate, nateglinide,
repaglinide, rifampicin) concomitant administration should also be undertaken with caution. Patients
should be closely monitored for signs and symptoms of excessive exposure to the medicinal
products and reduction of the dose of these medicinal products should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) sulfasalazine (HOS-089673) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) nateglinide (HOS-089675) topotecan (HOS-086047) doxorubicin (HOS-084538) repaglinide (HOS-086935) pravastatin (HOS-086306) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-07T09:36:00Z · SHA-256 cd6bb826d7f71e10dd6cea956a4c1d40ef339b9461b69d87c77735d5508df2d9 · Passage f37465d9d3fa779177b38c1116c6d5221ab029de8d593b9e1a786c9960c38e00 · Zeichen 5489–6463 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090627 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6798–7049 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090690 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6745–6996 im Abschnitt
Wechselwirkungen · Targretin
Targretin 75 mg soft capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-091530 · Präparat HOS-084349
A population analysis of plasma bexarotene concentrations in patients with CTCL indicated that
concomitant administration of gemfibrozil resulted in substantial increases in plasma concentrations of
bexarotene. The mechanism of this interaction is unknown. Under similar conditions, bexarotene
concentrations were not affected by concomitant administration of atorvastatin or levothyroxine.
Concomitant administration of gemfibrozil with bexarotene is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) gemfibrozil (HOS-088403) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-12T12:14:00Z · SHA-256 3bf4d2f2fd7cbd6812f185953fbdb6223f58862715009080d9c1b2058c9f08b5 · Passage 95127a1fbfbf0994fcc90f8652f5ee9a65504a0d60b3fdf8bbfbddc7f138c142 · Zeichen 906–1374 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 24–25
HOS-108934 · Präparat HOS-093083
24
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended.
Cmax: ↑ 4.7-fold If the use of atorvastatin is
Due to CYP3A inhibition by considered strictly necessary, the
lopinavir/ritonavir. lowest possible dose of
atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be
Cmax: ↑ 5-fold considered when Kaletra is
While rosuvastatin is poorly co-administered with rosuvastatin
metabolised by CYP3A4, an (see section 4.4).
increase of its plasma
concentrations was observed.
The mechanism of this interaction
may result from inhibition of
transport proteins.
Fluvastatin or Pravastatin Fluvastatin, Pravastatin: If treatment with an HMG-CoA
No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg QD Buprenorphine: ↔ No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) lomitapide (HOS-086160) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a27011337575de5ab6a9cbb05a4ed667b9b72fba13fff3beebbce86283b037b · Zeichen 57600–59815 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-109022 · Präparat HOS-093083
59
Herbal products
St John’s wort Lopinavir: Herbal preparations containing St
(Hypericum perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels. Lopinavir
and ritonavir levels may increase on
stopping St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra can
be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors may
concentrations due to CYP3A cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest possible
lopinavir/ritonavir. dose of atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered with
While rosuvastatin is poorly rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin reductase inhibitor is indicated,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 828eb1430737116e7e38afe94ac9495cef2e1489ddb625df82544aac21c48455 · Zeichen 52305–56991 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96
HOS-109101 · Präparat HOS-093083
95
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest
lopinavir/ritonavir. possible dose of atorvastatin should
be administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered
While rosuvastatin is poorly with rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8615aceaaf9aeead58e7d8428a116c5869ad8f9e57e471dff2f6359133eeb12b · Zeichen 55116–58920 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 23
HOS-112115 · Präparat HOS-093615
The increase in progestin exposure may
lead to related side effects (e.g., insulin
resistance, dyslipidemia, acne and
spotting), thus possibly affecting the
compliance.
LIPID-MODIFYING AGENTS
HMG-CoA reductase inhibitors
Simvastatin Simvastatin and lovastatin are highly Co-administration of simvastatin or
Lovastatin dependent on CYP3A4 for their lovastatin with REYATAZ is
metabolism and co-administration with contraindicated due to an increased
REYATAZ may result in increased risk of myopathy including
concentrations. rhabdomyolysis (see section 4.3).
Atorvastatin The risk of myopathy including Co-administration of atorvastatin
rhabdomyolysis may also be increased with REYATAZ is not
with atorvastatin, which is also recommended. If the use of
metabolised by CYP3A4. atorvastatin is considered strictly
necessary, the lowest possible dose
of atorvastatin should be
administered with careful safety
monitoring (see section 4.4).
Pravastatin Although not studied, there is a potential Caution should be exercised.
Fluvastatin for an increase in pravastatin or fluvastatin
exposure when co-administered with
protease inhibitors. Pravastatin is not
metabolised by CYP3A4. Fluvastatin is
partially metabolised by CYP2C9.
Other lipid-modifying agents
Lomitapide Lomitapide is highly dependent on Co-administration of lomitapide
CYP3A4 for metabolism and co- and REYATAZ with ritonavir is
administration with REYATAZ with contraindicated due to a potential
ritonavir may result in increased risk of markedly increased
concentrations. transaminase levels and
hepatotoxicity (see section 4.3).
INHALED BETA AGONISTS
Salmeterol Co-administration with REYATAZ may Co-administration of salmeterol
result in increased concentrations of with REYATAZ is not
salmeterol and an increase in salmeterol- recommended (see section 4.4).
associated adverse events.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) salmeterol (HOS-086285) lead (HOS-085592) ritonavir (HOS-084521) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8b78bbc3e02ae5f0c1ee3136e8833b5a4db25ba5d80192d381b81c04949c1b1f · Zeichen 66846–70225 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 59
HOS-112201 · Präparat HOS-093615
The increase in progestin exposure may
lead to related side effects (e.g., insulin
resistance, dyslipidemia, acne and
spotting), thus possibly affecting the
compliance.
LIPID-MODIFYING AGENTS
HMG-CoA reductase inhibitors
Simvastatin Simvastatin and lovastatin are highly Co-administration of
Lovastatin dependent on CYP3A4 for their simvastatin or lovastatin with
metabolism and co-administration with REYATAZ is contraindicated
REYATAZ may result in increased due to an increased risk of
concentrations. myopathy including
rhabdomyolysis (see
section 4.3).
Atorvastatin The risk of myopathy including Co-administration of
rhabdomyolysis may also be increased with atorvastatin with REYATAZ is
atorvastatin, which is also metabolised by not recommended. If the use of
CYP3A4. atorvastatin is considered
strictly necessary, the lowest
possible dose of atorvastatin
should be administered with
careful safety monitoring (see
section 4.4).
Pravastatin Although not studied, there is a potential Caution should be exercised.
Fluvastatin for an increase in pravastatin or fluvastatin
exposure when co-administered with
protease inhibitors. Pravastatin is not
metabolised by CYP3A4. Fluvastatin is
partially metabolised by CYP2C9.
Other lipid-modifying agents
Lomitapide Lomitapide is highly dependent on Co-administration of
CYP3A4 for metabolism and co- lomitapide and REYATAZ
administration with REYATAZ with with ritonavir is
ritonavir may result in increased contraindicated due to a
concentrations. potential risk of markedly
increased transaminase levels
and hepatotoxicity (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) lead (HOS-085592) ritonavir (HOS-084521) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 44aa56d8a668b485784b1f653b51695f82980278276d44827d822987d189c2df · Zeichen 69471–72847 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-114226 · Präparat HOS-094063
Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 3331e92a973cb3f3e08093b7633bee90354bcab8f1b1895b90d6d5e6313bbc61 · Zeichen 455–570 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.3 · PDF-Seite 22
HOS-114278 · Präparat HOS-094063
Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 3331e92a973cb3f3e08093b7633bee90354bcab8f1b1895b90d6d5e6313bbc61 · Zeichen 455–570 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 44–45
HOS-114331 · Präparat HOS-094063
44
Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 889dff209681e57300d417d88026846b88bb927f95517fcc125ca73cf5086bf3 · Zeichen 507–626 im Abschnitt
Gegenanzeigen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.3 · PDF-Seite 68
HOS-114385 · Präparat HOS-094063
Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 3331e92a973cb3f3e08093b7633bee90354bcab8f1b1895b90d6d5e6313bbc61 · Zeichen 455–570 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 7
HOS-114241 · Präparat HOS-094063
HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and
atorvastatin)
Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are
metabolised by CYP3A4. Treatment with these HMG-CoA reductase inhibitors should be
discontinued during treatment with posaconazole as increased levels have been associated with
rhabdomyolysis (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage c4378e48bdb6d8a71c6cd8508207164e71e0cb4a4fc6cfe308e6381c698c34aa · Zeichen 5221–5631 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-114291 · Präparat HOS-094063
HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and
atorvastatin)
Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are
metabolised by CYP3A4. Treatment with these HMG-CoA reductase inhibitors should be
discontinued during treatment with posaconazole as increased levels have been associated with
rhabdomyolysis (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage c4378e48bdb6d8a71c6cd8508207164e71e0cb4a4fc6cfe308e6381c698c34aa · Zeichen 4695–5105 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.